加载中
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
常规交易时段
US$3.78
−US$0.23 · -5.74%
盘中时间采用ET。市场数据可能有所延迟。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日内区间
当前US$3.78
52周区间
当前US$3.78
盘中时间采用ET。市场数据可能有所延迟。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日内区间
当前US$3.78
52周区间
当前US$3.78
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3557.7万 USD | 756.6万 USD | 512.4万 USD | 903.2万 USD | 1200万 USD |
| 销货成本 | 344.1万 USD | 274万 USD | 74.6万 USD | 72.5万 USD | 47.2万 USD |
| 毛利 | 3213.6万 USD | 482.6万 USD | 437.8万 USD | 830.7万 USD | 1152.8万 USD |
| 研究与开发 | 885.5万 USD | 1184万 USD | 2029.5万 USD | 1219.8万 USD | 1592.9万 USD |
| 销售、一般及管理费用 | 3522万 USD | 5882.2万 USD | 4730.5万 USD | 1740.5万 USD | 2697.9万 USD |
| 营业费用 | 4407.5万 USD | 7074.5万 USD | 7013.7万 USD | 2960.3万 USD | 4243.6万 USD |
| 利息收入 | 92.9万 USD | 141.7万 USD | 274万 USD | 47.6万 USD | 12.3万 USD |
| 利息支出 | 774.2万 USD | 941.2万 USD | 396.2万 USD | 217.2万 USD | 429.5万 USD |
| 折旧和摊销 | 78.1万 USD | 126.9万 USD | 83.6万 USD | 71.8万 USD | 47.2万 USD |
| 营业利润 | −1193.9万 USD | −6591.9万 USD | −6575.9万 USD | −2129.6万 USD | −3090.8万 USD |
| 净利润 | −1788.6万 USD | −7657.9万 USD | −6699.5万 USD | −2448.7万 USD | −3508万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.00
上涨空间 138.10%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Avantis Total Equity Markets ETF 1AVTMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
